Here are the top 5 most-read pulmonary fibrosis articles of 2025.
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...
Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback